BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 8914388)

  • 1. [Chemotherapy of pulmonary Mycobacterium kansasii infection].
    Mizutani S
    Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
    Kawahara S; Nagare H
    Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of non-tuberculous pulmonary mycobacteriosis].
    Sakatani M; Nakajima Y
    Kekkaku; 2006 Jan; 81(1):35-50. PubMed ID: 16479999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of new quinolones in the treatment of mycobacteriosis].
    Kekkaku; 2003 Sep; 78(9):601-4. PubMed ID: 14577348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Investigation on the treatment of infection due to Mycobacterium Kansasii].
    Nakazono T; Sugie T; Ogata H; Mizutani S; Sugita H; Kino T; Wada M
    Kekkaku; 1994 Oct; 69(10):587-92. PubMed ID: 7799569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
    Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
    Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New drugs against tuberculosis and nontuberculous mycobacterial infections: a review].
    Amitani R; Kuze F
    Kekkaku; 1994 Nov; 69(11):711-7. PubMed ID: 7837725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-tuberculous mycobacteriosis. What has been coming out].
    Kajiki A
    Kekkaku; 2011 Feb; 86(2):113-25. PubMed ID: 21404655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of a newly developed broth microdilution test method to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for mycobacteria].
    Yamane N; Nakasone I; Saitoh H; Kaneda M; Shimojima M; Yamashita K; Toyoda K; Okazawa Y
    Rinsho Byori; 1998 Jul; 46(7):719-27. PubMed ID: 9721542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mycobacterium kansasii lung infection associated with myelofibrosis--a case refractory to treatment with antitubercular agents].
    Umeda A; Asano K; Kawai A; Nakamura H; Fujita H; Mori M; Yamaguchi K; Kanazawa M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1994 Dec; 32(12):1170-4. PubMed ID: 7853774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Perspective of pulmonary MAC infection treatment].
    Kurashima A
    Kekkaku; 2007 Mar; 82(3):195-9. PubMed ID: 17444124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features of pulmonary Mycobacterium kansasii infection: comparison with M. tuberculosis and M. avium complex infection].
    Matsushita Y; Niimi A; Tanaka E; Amitani R; Kurasawa T; Kawai M; Kuze F
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31(12):1507-14. PubMed ID: 8121086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic efficacy of macrolide in pulmonary nontuberculous mycobacteriosis].
    Tomono K
    Kekkaku; 1994 Nov; 69(11):725-32. PubMed ID: 7837727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to new macrolides, new quinolones, and antituberculous drugs on Dubos agar medium].
    Ogawa K; Miwa T; Sasamoto M; Sasaki T; Tsuda M; Honda K; Furui H; Torii K; Takagi K
    Kekkaku; 1992 Nov; 67(11):735-8. PubMed ID: 1487866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of combined chemotherapy following the guidelines on treatment for Mycobacterium avium complex pulmonary disease].
    Kobashi Y; Okimoto N; Matsushima T; Shigetou E; Kuraoka T; Takeyama H; Eda R; Yano S; Kobayashi K; Ohnishi T; Mori K; Ueda Y; Moritaka T; Nishimura K; Abe T
    Kekkaku; 2002 Jun; 77(6):435-41. PubMed ID: 12136597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of drug-resistant pulmonary tuberculosis treated successfully following disappearance of rifampicin resistance after 17 years' chemotherapy].
    Shigeto E; Murakami I; Yokosaki Y
    Kekkaku; 2001 Apr; 76(4):379-83. PubMed ID: 11398329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.